Olmesartan: 360-degree Perspectives Befitting an Angiotensin Receptor Blocker.

Area of Science:

• Cardiology and Internal Medicine
• Pharmacology and Therapeutics

Background:

• Hypertension (HTN) poses a significant health burden in India, frequently leading to poorly controlled blood pressure (BP) and hypertension-mediated organ damage (HMOD).
• Angiotensin receptor blockers (ARBs) are crucial first-line agents for managing hypertension across diverse patient groups.

Purpose of the Study:

• To provide a comprehensive review of olmesartan's efficacy in managing hypertension.
• To highlight olmesartan's dual role in reducing blood pressure and providing organ-protective effects.

Main Methods:

• Systematic review of existing clinical evidence and research on olmesartan.
• Analysis of studies focusing on olmesartan's impact on blood pressure control and organ damage markers.
• Examination of data on olmesartan's effects on microvascular inflammation, cardiac and vascular remodeling, and clinical outcomes.

Main Results:

• Olmesartan demonstrates high efficacy in achieving sustained 24-hour blood pressure reduction.
• Evidence supports olmesartan's protective role against hypertension-mediated organ damage, including reduced microvascular inflammation, left ventricular hypertrophy, proteinuria, and vascular stiffness.
• Olmesartan has been shown to decrease central aortic BP, cardiocerebrovascular events, and atrial fibrillation.

Conclusions:

• Olmesartan is a highly effective antihypertensive agent offering significant blood pressure lowering and organ protection.
• The availability of single-pill combinations with olmesartan can enhance therapeutic compliance and help achieve blood pressure goals.
• Olmesartan represents a valuable therapeutic option for comprehensive hypertension management, addressing both BP control and organ damage prevention.